At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union Medical Device Regulation certification, expanding its use to four body areas.
Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow’s feet (lateral canthal lines). Dysport® (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction after treatment of frown lines will also be presented.
Galderma has released new clinical data confirming Nemluvio® (nemolizumab)'s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.
Galderma announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO).
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms. Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body.
Galderma presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held in Chicago from November 13-16. Six poster presentations spotlighted the latest data on Galderma's Injectable Aesthetics portfolio, while a series of onsite educational events through the Galderma Aesthetic Injector Network (GAIN) further showcased Galderma’s commitment to advancing aesthetic medicine through science-backed solutions. Spanning key treatment areas, the findings reinforce Galderma’s leadership in delivering meaningful outcomes and addressing unmet patient needs through robust clinical evidence and practitioner education.
Today, we announced that the United States Food and Drug Administration has approved Restylane Lyft with Lidocaine for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion. Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also approved to treat the midface, facial folds and wrinkles (such as nasolabial folds) and back of hands.
Last week, we announced our financial results for the first nine months of 2025. Galderma achieved record net sales of 3.737 billion USD, representing year-on-year net sales growth of 15.0% at constant currency, driven predominantly by volume growth complemented by favorable mix. Net sales growth for the third quarter was ahead of expectations, in a market with some constrained consumer spending.
The world is transforming at a faster rate than ever. Organizations have no choice but to keep up with the rapidly evolving technologies that are shaping their industries. At Galderma, we advance our category leadership in dermatology by empowering high-performing IT teams that go above and beyond in their work. Working at Galderma means contributing not only to our growth as a company, but also to your own professional success. We offer personalized development opportunities so our talented people can grow their careers and reach their full potential.
Galderma marks the 10th anniversary of our premium medical skincare brand Alastin® by Galderma with the launch of four core products in China, one of the world’s fastest growing aesthetic skincare markets. As the demand for perioperative skincare accelerates, this expansion shows Galderma’s commitment to delivering science-backed products that drive superior outcomes for even more patients.
